MassBio CEO & President Kendalle Burlin O’Connell originally posted this update to LinkedIn:
With Congress out of Washington until after the November elections, the agencies continued to drive the life sciences policy agenda this week. Several developments are worth watching for Massachusetts biotechs, including the launch of a new FDA office focused on clinical trial modernization, an FDA roadmap outlining plans to make more of the regulatory process public, and the approaching October 16 deadline to comment on the FDA’s proposed PDUFA VIII agreement.
FDA Opens New Office for Clinical Trial Modernization: The FDA has launched a new Office of Innovation and Clinical Trial Modernization within CDER, housed in the Center’s Office of Medical Policy. The office consolidates the agency’s efforts to support innovative trial designs and will include two divisions, one dedicated to real-world evidence analytics and the other to artificial intelligence. The FDA says the new structure is intended to give sponsors earlier guidance on novel trial approaches and help new therapies reach patients sooner. The announcement follows the launch of the FDA’s expedited IND pilot last month, which officials say could help inform a future clinical trial notification system similar to Australia’s third-party protocol reviews. Alongside ARPA-H’s new SURPASS program, the initiatives reflect a broader federal focus on speeding up U.S. clinical development, and could give Massachusetts sponsors another avenue to engage the FDA on innovative trial designs. The new office aligns with priorities MassBio has long championed on Capitol Hill, as a modern, efficient clinical trial environment is essential to maintaining U.S. leadership in biotechnology.
FDA Releases Transparency Roadmap: The FDA released a Transparency Roadmap that outlines the progress the agency made in FY26 and its transparency agenda for FY27. Plans include continuing to publish complete response letters, pursuing rulemaking to disclose when major applications, including NDAs and BLAs, are submitted, and encouraging sponsors to disclose IND filings. The FDA also plans to publish redacted Clinical Study Reports for approved applications, improve compliance with ClinicalTrials.gov reporting requirements, and proactively release redacted Form 483s and inspection reports where appropriate. The Transparency Roadmap also points to an August agreement between the FDA and SEC that allows the agencies to share nonpublic information, which the SEC can use to review company filings and support enforcement actions. For Massachusetts companies, the roadmap is another sign that the FDA is shifting toward greater public disclosure of regulatory decisions, with real implications for how companies communicate FDA developments to investors.
PDUFA VIII Comments Due October 16: FDA’s proposed PDUFA VIII recommendations, which would cover fiscal years 2028 through 2032, refine the existing drug review program while adding new ways for sponsors to engage with the agency. The commitment letter includes multi-divisional meetings for products developed across therapeutic areas, the ability to request face-to-face pre-IND, Type C, Type D, and INTERACT meetings, new pre-submission and post-inspection meetings to address manufacturing facility issues, and the integration of model-informed drug development and rare disease endpoint programs into the FDA’s formal meeting system. The Federal Register notice also proposes fee changes to encourage early-stage research in the U.S., including a 50% reduction in the application fee for submissions with clinical data from a U.S.-based Phase 1 trial started after October 1, 2027, and limiting small-business fee waivers to U.S. companies. MassBio will submit comments before the October 16 deadline.
Senate HELP Committee Advances Health Nominees: The Senate HELP Committee voted 12-11 along party lines to advance three HHS nominees: Nicole Saphier for Surgeon General, Timothy Westlake for Assistant Secretary for Mental Health and Substance Use, and Mary Lazare for Assistant Secretary for Aging. Full Senate votes are not expected until after the November midterms. With several key HHS confirmations now pushed beyond the midterms, parts of the department’s leadership structure are likely to remain unsettled through the end of the year.
